DTaP-IPV/Hib
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Haemophilus Infections
Conditions
Haemophilus Infections, Diphtheria, Tetanus, Polio, Pertussis
Trial Timeline
Feb 1, 2009 → Dec 1, 2014
NCT ID
NCT00855855About DTaP-IPV/Hib
DTaP-IPV/Hib is a pre-clinical stage product being developed by Sanofi for Haemophilus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00855855. Target conditions include Haemophilus Infections, Diphtheria, Tetanus.
What happened to similar drugs?
2 of 9 similar drugs in Haemophilus Infections were approved
Approved (2) Terminated (0) Active (7)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00855855 | Pre-clinical | Completed |
Competing Products
10 competing products in Haemophilus Infections
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Comparator: Modified Process Vaccine + Comparator: COMVAX™ | Merck | Phase 3 | 40 |
| Vaxelis + PedvaxHIB | Merck | Approved | 43 |
| Haemophilus influenzae type b (Hib) vaccine | Novartis | Phase 3 | 40 |
| Haemophilus influenzae type b (Hib) vaccine | Novartis | Phase 3 | 40 |
| Haemophilus influenza type b conjugate vaccine | Novartis | Approved | 43 |
| Hib-CRM197 + Hib-TT | Novartis | Phase 3 | 40 |
| Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine) + Hiberix (Haemophilus influenzae type b (Hib) vaccine) | Novartis | Phase 3 | 40 |
| Haemophilus influenzae type b | Novartis | Phase 1 | 29 |
| Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib) + Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib) | Novartis | Phase 3 | 40 |
| Haemophilus influenzae type b vaccine + Commercial Haemophilus influenzae type b vaccine | Novartis | Phase 3 | 40 |